Introductory Chapter: Skeletal Muscle Disorders – Emerging New Avenues for the Diagnosis and Treatment
Author:
Arturo Iannotti Fabio
Reference26 articles.
1. Salari N, Fatahi B, Valipour E, Kazeminia M, Fatahian R, Kiaei A, et al. Global prevalence of Duchenne and Becker muscular dystrophy: A systematic review and meta-analysis. Journal of Orthopaedic Surgery and Research. 2022;17:96. DOI: 10.1186/s13018-022-02996-8
2. Sheikh O, Yokota T. Advances in genetic characterization and genotype-phenotype correlation of Duchenne and Becker muscular dystrophy in the personalized medicine era. Journal of Personalized Medicine. 2020;10:111. DOI: 10.3390/jpm10030111
3. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. The Lancet Neurology. 2010;9:77-93. DOI: 10.1016/S1474-4422(09)70271-6
4. Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123-2131. DOI: 10.1212/WNL.0000000000003217
5. Lamb MM, West NA, Ouyang L, Yang M, Weitzenkamp D, James K, et al. Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy. The Journal of Pediatrics. 2016;173:207-213.e3. DOI: 10.1016/j.jpeds.2016.02.067